HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial.

AbstractIntroduction:
More information is needed about the safety of low-dose primaquine in populations where G6PD deficiency is common.
Methods:
Adults with Plasmodium falciparum malaria were randomized to receive 1 of 3 artemisinin combination therapies (ACTs) with or without primaquine (0.25 mg/kg). Glucose-6-phosphate dehydrogenase (G6PD) status was determined using a rapid test. Patients were followed for 28 days to record hemoglobin concentration, adverse events, and gametocyte carriage. The primary end point was the change in Hb at day 7.
Results:
In sum, 274 patients were randomized, 139 received an ACT alone, and 135 received an ACT + primaquine. The mean reduction in Hb at day 7 was similar in each group, a difference in the ACT + PQ versus the ACT alone group of -0.04 g/dL (95% confidence interval [CI] -0.23, 0.31), but the effect of primaquine differed according to G6PD status. In G6PD-deficient patients the drop in Hb was 0.63 g/dL (95% CI 0.03, 1.24) greater in those who received primaquine than in those who received an ACT alone. In G6PD-normal patients, the reduction in Hb was 0.22 g/dL (95% CI -0.08, 0.52) less in those who received primaquine (interaction P = .01). One G6PD normal patient who received primaquine developed moderately severe anaemia (Hb < 8 g/dL). Dark urine was more frequent in patients who received primaquine. Primaquine was associated with a 73% (95% CI 24-90) reduction in gametocyte carriage (P = .013).
Conclusion:
Primaquine substantially reduced gametocyte carriage. However, the fall in Hb concentration at day 7 was greater in G6PD-deficient patients who received primaquine than in those who did not and one patient who received primaquine developed moderately severe anemia.
Clinical Trial registration:
PACTR201411000937373 (www.pactr.org).
AuthorsRoger C Tine, Khadime Sylla, Babacar T Faye, Eugenie Poirot, Fatou B Fall, Doudou Sow, Duolao Wang, Magatte Ndiaye, Jean Louis Ndiaye, Babacar Faye, Brian Greenwood, Oumar Gaye, Paul Milligan
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 65 Issue 4 Pg. 535-543 (08 15 2017) ISSN: 1537-6591 [Electronic] United States
PMID28605472 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.
Chemical References
  • Antimalarials
  • Hemoglobins
  • Primaquine
Topics
  • Adolescent
  • Adult
  • Aged
  • Antimalarials (administration & dosage, adverse effects, therapeutic use)
  • Female
  • Hemoglobins
  • Humans
  • Malaria, Falciparum (blood, drug therapy, parasitology, physiopathology)
  • Male
  • Middle Aged
  • Parasitemia
  • Plasmodium falciparum
  • Primaquine (administration & dosage, adverse effects, therapeutic use)
  • Senegal
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: